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Abstract
Background: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency is caused by deletions, large gene 
conversions or mutations in CYP21A2 gene. The human gene is located at 6p21.3 within a locus containing the genes 
for putative serine/threonine Kinase RP, complement C4, steroid 21-hydroxylase CYP21 tenascin TNX, normally, in a 
duplicated cluster known as RCCX module. The CYP21 extra copy is a pseudogene (CYP21A1P). In Brazil, 30-kb deletion 
forming monomodular alleles that carry chimeric CYP21A1P/A2 genes corresponds to ~9% of disease-causing alleles. 
Such alleles are considered to result from unequal crossovers within the bimodular C4/CYP21 locus. Depending on the 
localization of recombination breakpoint, different alleles can be generated conferring the locus high degree of allelic 
variability. The purpose of the study was to investigate the variability of deleted alleles in patients with 21-hydroxylase 
deficiency.
Methods: We used different techniques to investigate the variability of 30-kb deletion alleles in patients with 21-
hydroxylase deficiency. Alleles were first selected after Southern blotting. The composition of CYP21A1P/A2 chimeric 
genes was investigated by ASO-PCR and MLPA analyses followed by sequencing to refine the location of 
recombination breakpoints. Twenty patients carrying at least one allele with C4/CYP21 30-kb deletion were included in 
the study.
Results: An allele carrying a CYP21A1P/A2 chimeric gene was found unusually associated to a C4B/C4A Taq I 6.4-kb 
fragment, generally associated to C4B and CYP21A1P deletions. A novel haplotype bearing both p.P34L and p.H62L, 
novel and rare mutations, respectively, was identified in exon 1, however p.P30L, the most frequent pseudogene-
derived mutation in this exon, was absent. Four unrelated patients showed this haplotype. Absence of p.P34L in 
CYP21A1P of normal controls indicated that it is not derived from pseudogene. In addition, the combination of different 
approaches revealed nine haplotypes for deleted 21-hydroxylase deficiency alleles.
Conclusions: This study demonstrated high allelic variability for 30-kb deletion in patients with 21-hydroxylase 
deficiency indicating that a founder effect might be improbable for most monomodular alleles carrying CYP21A1P/A2 
chimeric genes in Brazil.
Background
Congenital adrenal hyperplasia (CAH) is an autosomal
recessive inborn error of metabolism due to the defi-
ciency of one of the enzymes involved in the adrenal ste-
roidogenesis [1]. More than 95% of the cases are due to
deficiency of 21-hydroxylase enzyme (21-OHD; OMIM
+201910). Diminished or absent 21-hydroxylase activity
leads to reduction or abolishment of cortisol and aldos-
terone syntheses, consequently, an over production of
androgens occurs [1,2]. Different clinical presentations
are classified in classical form that can be salt-wasting
(SW) or simple-virilizing (SV), and late-onset non-classi-
cal (NC) form [1-3]. Mutations on CYP21A2 gene, which
encodes the enzyme, are responsible for the disease [2,3].
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The CYP21A2 gene and CYP21A1P, its pseudogene, are
located within the class III locus of the human major his-
tocompatibility complex at the short arm of chromosome
6 [4,5]. Both have 10 exons, except that CYP21A1P  is
inactive due to deleterious mutations [6,7]. Approxi-
mately 30 kb separate CYP21A2 from CYP21A1P. The
genes of the fourth component of complement C4A and
C4B, also map to this locus and are located, respectively,
upstream and downstream to the CYP21A1P [4,5].
In addition other genes, such as RP1 and TNXB and
their truncated gene fragments or pseudogenes, RP2 and
TNXA, are present within this genetic unit [8]. Each RP,
C4, CYP21, TNX copy together forms the RCCX module
[8] that maps within approximately 30 kb [9-11]. In gen-
eral, 70% of alleles are bimodular (two RCCX units) in
most populations [12]. Nevertheless, monomodular
(16%), and trimodular (14%) alleles with long and short
C4B gene variants are not uncommon [12].
Deletion or duplication of CYP21A1P  or  CYP21A2
together with C4A or C4B always occurs [8,13-15]. The
deletion and large gene conversion were the first muta-
tions described in 21-hydroxylase deficiency alleles [16-
19]. Generally, disease-causing 30-kb deletions extend
from 3'end CYP21A1P  and include C4B  and 5' end
CYP21A2 to form inactive CYP21A1P/A2 chimeric genes
[20-27]. Whereas monomodular alleles with C4A/C4B
chimeric genes may also be formed after unequal cross-
overs, they are frequently associated to a functional
CYP21A2 gene copy [13,22]. Such rearrangements can be
recognized in Southern blots using Taq  I restriction
enzyme where C4 and  CYP21 chimeric genes produce
6.4- and 3.2-kb fragments, respectively [22,23]. Deletions,
large gene conversions and duplications may be evaluated
either by Southern blot [3] or by the recently developed
Multiplex Ligation-dependent Probe Amplification
(MLPA) technique [24]. As CYP21A1P/A2  chimeric
genes may carry different pseudogene-derived mutations,
disease-causing deletion alleles may vary according the
chimeric gene composition [21,22,25,26]. Novel
CYP21A1P/A2  chimeric genes have been continuously
described in different studies [27,28].
In Brazil, 30-kb deletion monomodular alleles corre-
spond to ~9% of disease-causing alleles [29,30]. The pres-
ent study describes the variability of such alleles in
Brazilian patients (n = 20) with 21-hydroxylase deficiency
using the conventional Southern blot, ASO-PCR and
sequencing techniques combined to recently developed
MLPA technique. Nine different and two novel mono-
modular haplotypes are reported. A 6.4-kb Taq  I frag-
ment corresponding to a C4B/C4A  chimeric gene was
unusually associated to CYP21A1P/A2  chimeric gene
that also bore novel and rare single nucleotide polymor-
phisms (SNPs). Another allele was identified with a
CYP21A1P/A2  gene carrying both p.P34L and p.H62L
mutations in exon 1, however p.P30L, the most frequent
pseudogene-derived mutation in this exon, was absent.
The study of 59 healthy controls revealed that the novel
p.P34L mutation is not pseudogene-derived and occurred
only in alleles carrying the 30-kb deletion whereas the
rare p.H62L mutation can be pseudogene-derived since it
was found in 3.4% pseudogene sequences.
Methods
Subjects
This study was approved by the Ethics Committee from
Universidade Estadual de Campinas (São Paulo, Brasil)
and an informed consent was obtained from patients and
relatives.
Twenty patients (8 males, 12 females) with 21-hydroxy-
lase deficiency were included in this study (table 1). They
represent 20 unrelated families. Consanguinity was
reported in two families. Fourteen patients presented
with the salt-wasting (SW) form, whereas five manifested
the simple-virilizing (SV) form and one with the non-
classic form (NC). Fifty-two family members were geno-
typed. Fifty non-related health individuals were screened
for novel and rare mutations.
Methods
Southern blot and Allele-specific PCR (ASO-PCR)
Genomic DNA was obtained from peripheral blood by
Proteinase K digestion and phenol/chloroform extraction
[31]. Southern blots with Taq I digested DNA were per-
formed following standard procedures [31]. Membranes
were hybridized with CYP21 (pC21/3c) and C4 (C4B550)
probes [29]. The probes were radiolabeled in a random
priming reaction (Invitrogen, CA, USA) with α-32P-dCTP
(Amersham, Uppsala, Sweden). The blots were washed
using conventional conditions [31] and a final wash using
0.1 × SSC/0.1% SDS at 65°C was performed. Autoradiog-
raphies on Hyperfilm MP X-ray films (Amersham) were
obtained. Blots were analysed following Taq I RFLP in C4
and CYP21 genes (Figure 1a) and relative band intensi-
ties.
ASO-PCR was performed with primers for the eight
most common CYP21A1P-derived mutations as
described elsewhere [32]. Six single nucleotide polymor-
phisms (SNPs) were also investigated either using ASO-
PCR with primers specifically designed on basis the gene
sequences or by digestion with restriction enzymes.
Primers for exon 6 normal or mutant sequences (CL6N
or Cl6M) were used as selective primers. As pseudogenes
are also amplified in the analysis of CYP21A1P/A2 chi-
meric genes with exon 6 mutant primer, chimeric genes
were identified upon analysis of all family members.
Multiplex Ligation-dependent Probe Amplification (MLPA)
MLPA was performed exactly as recommended by the
manufacturers using SALSA MLPA P050B kit (MRC-Coeli et al. BMC Medical Genetics 2010, 11:104
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Holland, Amsterdam, Netherlands) [33]. Fragment analy-
sis was performed on an ABI 310 Genetic Analyzer (ABI
PRISM/PE Biosystems, Foster City, CA, USA) and results
were analyzed using Genescan and Genotyper softwares
(Applied Biosystems, Foster City, CA, USA). Calculations
were performed according to the method described by
Taylor et al. [34]. The probemix included in the MLPA kit
contains probes for several regions within CYP21 locus
(Figure1b). Data were analysed using free Coffalyser
M LP A  da t a  a n a l ys is  so ft wa r e  [ 3 3] .  N o rm a l iz ed  r e la t i v e
values ranging from 0.8 to 1.2 corresponded to two gene
copies in the genotype, whereas values below 0.8 and
above 1.2 corresponded to deletion (one gene copy) and
duplication (three gene copies), respectively. This confi-
dence interval was established by data obtained with five
bimodular controls in each MLPA assay.
Sequencing
A fragment including 600 bp from 5' promoter region to
exon 6 (CL6N or CL6M) and a fragment from exon 6 to
3'UTR (CL6N or CL6M) were first amplified. The frag-
ments were directly sequenced with internal primers
using Big Dye™ Terminator Cycle Sequencing Kit V3.1
Ready Reaction (ABI PRISM/PE Biosystems). The
sequences obtained in an ABI 3700 Automated
Sequencer (ABI PRISM/PE Biosystems) were compared
to  CYP21A2  and  CYP21A1P  sequences (Ensembl -
ENSG00000231852 and ENSG00000204338, respec-
tively).
Results
Southern blot analysis with CYP21 and C4 probes was
performed to distinguish deletions from large gene con-
versions. ASO-PCRs using CL6N or CL6M sequences as
selective primers were performed to investigate both
pseudogene-derived mutation and polymorphisms pres-
ent in chimeric CYP21A1/A2 and CYP21A2 genes. All
family members have been analyzed; therefore, pseudo-
genes and chimeric genes carrying CL6M sequences
could be distinguished. Southern blot revealed 30-kb
deletion in 20 patients with different genotypes (table 2;
Figure 2).
MLPA technique was used to confirm Southern blot
results and to obtain data on the composition of chimeric
Table 1: Clinical data of CAH patients
Case Sex1 Age at diagnosis2 Clinical Data basal 17OHP (nmol/L) Na+ /K+ (mmol/L) Phenotype3
1 M 1 m 28 d vomiting, dehydration na4 129/6.2 SW
2 F 12 d ambiguous genitalia; Prader III > 20 ndm5 137/6.2 SW
3 M 2 m 24 d vomiting, dehydration 49.3 116/9.2 SW
4 F 19 d vomiting, dehydration; registered as male na 128/7.8 SW
5 M 31 d vomiting, dehydration > 20 ndm 120/5.5 SW
6 M 2 m 8 d vomiting, dehydration > 200 ndm 121/6.8 SW
7 F 10 m ambiguous genitalia; Prader III > 25 ndm 142/5.0 SV
8 F 6 d ambiguous genitalia; Prader III/IV > 200 ndm 123/7.4 SW
9 F np ambiguous genitalia; Prader IV SW
10 M 1 yr 1 m vomiting, dehydration > 25 ndm 120/6.8 SW
11 F 6 yr 3 m precocious pubarche since 4 yr 6 m; high 
stature
> 25 ndm nt NC
12 F 10 d ambiguous genitalia; Prader III > 20 ndm 121/6.5 SW
13 F np ambiguous genitalia; Prader III/IV; vomiting, 
dehydration; registered as male
na na SW
14 F np ambiguous genitalia; Prader III na na SW
15 F 14 d ambiguous genitalia; Prader IV > 6 ndm 119/5.3 SW
16 M 28 d vomiting, dehydration, adrenal crysis > 200 ndm 119/9.7 SW
17 M 3 yr 5 m precocious pubarche since 2 yr > 20 ndm na SV
18 M 6 yr precocious pubarche > 20 ndm na SV
19 F 5 yr 7 m precocious pubarche, ambiguous genitalia; 
Prader IV
238 na SV
20 F 37 d ambiguous genitalia; Prader III > 20 ndm 136/5.7 SV
1F = Female, M = male; 2yr = years, m = months, d = days, np = neonatal period; 3SW = salt-wasting, SV = simple virilizing, NC = non-classic; 4na 
= not available; 5ndm = non-diluted measurements (ref value 5.97 nmol/L).Coeli et al. BMC Medical Genetics 2010, 11:104
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genes since it includes one probe for each C4A and C4B
genes, and three and five probes, respectively, for
CYP21A1P and CYP21A2 genes (Figure 1b). The MLPA
kit available also analyzes TNXB  located within the
RCCX locus and CREBL1 on chromosome 6p21.3 and
nineteen control genes as well. For all patients, normal-
ized data showed two copies for TNXB  and  CREBL1
genes (Figure 3) on chromosome 6 and also for control
genes (data not shown) indicating no copy number varia-
tion in other loci.
After sequencing CYP21A1P/A2 chimeric genes, novel
mutations and novel single nucleotide polymorphisms
(SNPs) have been identified. Haplotypes were classified
according to C4 gene characteristics and SNPs and muta-
tions present in CYP21A1P/A2 chimeric genes. Table 3
shows nine different haplotypes for monomodular alleles
identified in this study.
Patients 1 and 2, who were children of consanguineous
marriages, were homozygous for a monomodular allele.
However, hybridization results with C4 probe indicated a
6.4-kb Taq I fragment in patient 2, whereas patient 1 pre-
sented the usual 7.0-kb C4A fragment (Figure 2a). Molec-
ular investigation on patient's 2 family demonstrated that
the novel allele has been transmitted through three gen-
erations (data not shown). MLPA indicated similar com-
position of CYP21A1P/A2 chimeric genes in both cases
(Figure 3a, upper panel), but once again the two patients
differed in the C4  gene composition (Figure 3a, lower
panels). Patient 2, who carried the 6.4-kb Taq I fragment,
presented MLPA signal for two copies only for C4A
probe, whereas patient 1, who carried the 7.0-kb C4A Taq
I fragment, showed signals for two copies of C4A and
C4B probes, suggesting that both C4 in the genotype have
exon 19 sequences corresponding to C4B gene. There-
fore, the two different C4 sequence compositions indicate
Figure 2 Taq I Southern blots showing patients carrying mono-
modular alleles. Hybridizations with CYP21 (pC21/3c) and C4 (C4B550) 
probes are shown. a) Homozygous genotypes for monomodular al-
leles; b) compound heterozygous genotypes with mono- and bimod-
ular alleles carrying large gene conversion; c) compound heterozygous 
genotypes with mono- and bimodular alleles carrying pseudogene-
derived mutations; d) compound heterozygous genotype with mono- 
and trimodular alleles carrying pseudogene-derived mutations; e) 
compound heterozygous genotype with mono- and tetramodular al-
leles (lane 3); maternal genotype showing compound heterozygosis 
with mono- and bimodular alleles (lane 2); and paternal genotype with 
tetramodular and bimodular alleles (lane 1). Numbers below each lane 
depict patient numbers.
Table 2: Genotypes of CAH patients
Patients Genotype
Paternal Allele Maternal Allele
1 30-kb del1 30-kb del
2 30-kb del 30-kb del
3 LGC2 30-kb del
43 0 - k b  d e l L G C
5 IVS2-2A > G 30-kb del
6 30-kb del c.920_921insT
7 p.I172N 30-kb del
8 30-kb del p.P30L
9 p.W19X 30-kb del
10 p.Q318X 30-kb del
11 30-kb del p.V281L
12 30-kb del IVS2-13A/C > G
13 p.R356W 30-kb del
14 IVS2-13A/C > G 30-kb del
15 c.920_921insT 30-kb del
16 30-kb del p.R356W
17 p.I172N 30-kb del
18 30-kb del p.Q318X
19 30-kb del p.I172N
20 30-kb del IVS2-13A/C > G
130-kb del = deletion of 30 kb including 3'-end CYP21A1P, C4B 
and 5'-end CYP21A2,
2LGC = large gene conversion;
Figure 1 Schematic representation illustrating the hybridization 
sites for C4 and CYP21 probes. a) Southern blot: bars indicate hybrid-
ization regions for each probe; T denote Taq I restriction sites; numbers 
indicate sizes in kb of fragments recognized by each probe; b) MLPA 
experiment: arrows indicate the location where each probe hybridizes. 
Ex = exon, Int - intron.Coeli et al. BMC Medical Genetics 2010, 11:104
http://www.biomedcentral.com/1471-2350/11/104
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distinct 30-kb deletion alleles. Patient 1 showed haplo-
type II (table 3) that, besides the C4A/B chimeric copy,
also presented the C allelic variant at both -4 (SNP-
rs6470) and g.395 (SNP-rs6462) nucleotides. Haplotype I
is unique for patient 2 (table 3). In addition to the C4B/
A[6.4]  gene, it carries the novel -289T > C SNP in
CYP21A1P/A2 promoter region. The T variant at g.395
(SNP-rs6462) nucleotide and the rare pseudogene-
Figure 3 Integrated and normalized MLPA data. C4A, C4B, CYP21A1P, CYP21A2, TNXB, CREB1 are shown. Numbers 1-15 correspond to: (1) C4A exon 
17, (2) C4B exon 19, (3-5) CYP21A1P 5' promoter region, intron 2, 3'UTR; (6-10) CYP21A2 5' promoter region, exon 3, exon 4, exon 6, exon 8; (11-13) TNXB 
exon 32, 15, 1; (14) CREB1 probe. (15) Y-chromosome probe. Horizontal black bars denote recombination breakpoints (RB); red bar, for patient 8. Col-
umns correspond to integrated and normalized electropherogram peak areas, values between 0.8 and 1.2 indicate two copies, below and above cor-
respond to one or more than two copies, respectively. Patients' numbers are on the right. Green arrows indicate heterozygosis for p.I172N and 
p.Q318X (patient 18). Black arrows indicate 2:1 ratio for two copies of 3'UTR pseudogene (5) and one copy of exon 8 (10). (a-g) Upper panels - MLPA 
results; lower panels - schematic genotypes. a) Monomodular homozygosis; red circles denote different C4 5'-end; b) Mono- and bimodular alleles 
carrying chimeric genes; red arrows indicate 1:2 ratio (C4A:C4B); c) heterozygosis for mono- and bimodular alleles; red arrows indicate three copies of 
C4B; d) heterozygosis for mono- and tri- or tetramodular alleles; red arrows indicate 2:2 ratio for 3'-end CYP21A1P (5) to exon 8 CYP21A2 (10); patient 
10 - trimodular allele bearing normal p.Q318 in the two pseudogenes; e) heterozygosis for alleles mono- and bimodular with CYP21A1P/A2 and C4A/
C4B, respectively; f-g) heterozygosis for mono- and bimodular alleles; RB between exons 3-4 and 1-3, respectively; red arrow - null C4B hybridization 
signal (patient 20).C
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Table 3: Haplotypes for monomodular alleles defined on basis of C4 and CYP21A1P/A2 chimeric gene
Haplotypes I II III IV V VI VII VIII IX
Patients 2 1 5 6 7 4 8 3 10 15 16 9 11 12 13 14 17 18 19 20
C4 Sb1 6 . 4 7777 7 7 7777777777777
MLPA2 B / A A / B A / B A / B A / BA A AAAAAAAAAAAAA
CYP21A1P/A2 5' RB3 6/8 6/8 6/8 6/8 6/8 3'end 3'end 3/4 3/4 3/4 3/4 3/4 3/4 3/4 3/4 3/4 3/4 1/3 1/3 1/3
-4494 AAAAA A - AAAAAA - GGGAAA
-3085 CCCCC C - GGGGCC - CCCCCC
-2896 CTTTT T - TTTTTT-TTTTTT
-47 TCCCC T T CC C CTTTTTTTTT
E1 p.P30L8 TTTTT T T CCCC-TTT-TTTT
p.P34L9 CCCCC C C TTTT - CCC-CCCC
p.H62L10 AAAAA A A TTTT - AAAAAAAA
I2 39511 TCCCC T T CCCCCCCTTTCCC
41912 - - - - - C C CCCCCCCCCCCCA
54713 - -A- - A A AA-AAAAA-AAAC
560_566insG14 - 6Gs 6Gs - 6Gs 6Gs 6Gs 6Gs 6Gs - 6Gs 6Gs 6Gs 6Gs 6Gs - 6Gs 6Gs 6Gs 7Gs
60215 AAAAA A A AA-AAAAA-ACCC
E 4 p . I 1 7 2 N AAAAA A A TTTTTTTTTTTTT
I5 125316 AGGGG G G GGGGGGGGGG - - -
E7 p.S268T17 GCCCC C G GGGGGGGGGGGGG
p.V281L18 TTTTT T T GGGGGGGGGGGGGC
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E8 p.Q318X19 CCCCC T T CCCCCCCCCCCCC
p.R356W20 CCCCC C T CCCCCCCCCCCCC
Numbers are relative to ATG initiation codon in the genomic DNA based on CYP21A2 sequence described by Higashi et al. (1986); mutation caused by nucleotide changes; E, exon; I, intron. 1Sb, size 
(kb) of C4 Taq I restriction fragments obtained in Southern blots. 2Composition of the C4 gene copy in monomodular alleles indicated by MLPA assays - A, corresponds to C4A and B, to C4B genes. 
3RB recombination breakpoint in CYP21A1P/A2 chimeric gene indicated by MLPA and ASO-PCR experiments; 6/8, between exons 6 an 8; 3/4, between exons 3 an 4; 1/3, between exons 1 an 3. 
CYP21A1P /CYP21A2 consensus nucleotides for polymorphic positions (number at NCBI-SNP database), most frequent nucleotide for each SNP is indicated first: 4A > G (rs28361032)/A (non-
polymorphic); 5C (non-polymorphic)/C > G (rs3130676); 6T (non-polymorphic)/T (non-polymorphic); 7T > C (rs6470)/C > T (rs6470); 8T > C (rs9378251)/C > T (rs9378251); 9C (non-polymorphic)/C (non-
polymorphic); 10A > T (rs9378252)/A > T (rs9378252); 11C > T (rs28361033)/T > C > G (rs6462); 12A (non-polymorphic)/A > C (rs6448); 13A(non-polymorphic)/C (non-polymorphic); 146Gs (non-
polymorphic)/7Gs > 6Gs (not registered); 15A(non-polymorphic)/C > A > G (rs6451); 16G > A (rs28691121)/G (non-polymorphic); 17G (non-polymorphic)/G > C (rs6472); 18T > G (rs41315836)/G > T 
(rs6471); 19T > C (rs7755898)/C > T (rs7755898); 20T > C (rs7755898)/C > T (rs7769409).
Table 3: Haplotypes for monomodular alleles defined on basis of C4 and CYP21A1P/A2 chimeric gene (Continued)Coeli et al. BMC Medical Genetics 2010, 11:104
http://www.biomedcentral.com/1471-2350/11/104
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derived g.1253A variant (SNP-rs28691121) were also
detected (table 3).
Patients 3 and 4 presented Southern blot results com-
patible with compound heterozygosis for 30-kb deletion
and large gene conversion in which no signal for 3.7-kb
CYP21A2 fragment was observed, whereas C4A[7.0] and
C4B[6.0] fragments were present with intensities of 2:1
(Figure 2b). In MLPA experiments C4A:C4B  ratios for
patients 3 and 4 were 2:1 and 1:2, respectively (Figure 3b,
upper panel). Both showed MLPA profiles compatible
with mono-/bimodular compound heterozygosis with
two different CYP21A1P/A2 chimeric genes (Figure 3b).
However, the composition of monomodular allele in each
case could only be defined after MLPA analysis of their
parents (data not shown). For patient 3, the breakpoint
between exon 3 and 4 in the chimeric CYP21A1P/A2
gene was defined for the paternal inherited monomodu-
lar allele. The maternal inherited bimodular allele carry-
ing large gene conversion presented a complete
pseudogene sequence indicated by the 2:1 ratio for
probes CYP21A1P-3'end and CYP21A2-exon 8 in MLPA
(Figure 3b, left lower panel) instead of the 1:2 expected if
it was a chimeric gene with CYP21A2-3'end. Similar
results were obtained for patient 4 except that in this case
the complete pseudogene was concluded to be associated
to the monomodular allele, whereas the chimeric
CYP21A1P/A2  gene with recombination breakpoint
between exon 3 and 4 was associated to the bimodular
allele with large gene conversion (Figure 3b, right lower
panel). In addition, based on MLPA analysis of her par-
ents (data not shown), the maternal bimodular allele in
patient 4 demonstrated to carry one of C4  copies in
which C4A probe could not hybridize; therefore the 1:3
ratio observed in her mother indicated absence of C4A
exon 17 sequences and presence of C4B  exon 19
sequences which is suggestive of a chimeric C4A/B gene
or a gene conversion at exon 17 (Figure 3b, right lower
panel). Considering C4 composition and CYP21A1P/A2
SNPs, the 30-kb deleted alleles in patients 3 and 4 corre-
spond to haplotypes V and III, respectively (table 3). Hap-
lotype V is defined by the presence of the novel p.P34L
and the rare p.H62L mutations, but absence of the
pseudogene-derived p.P30L, in exon 1. The variant -308G
and the variant C at -4 and g.395 nucleotides character-
ized this haplotype in which the recombination break-
point was located between exon 3 and 4.
For other sixteen patients (5-20) who were compound
heterozygous with monomodular and bi-, tri- or a proba-
ble tetramodular alleles bearing pseudogene-derived
mutations in the CYP21A2 gene (Figure 2c-e; table 2), dif-
ferent  C4A to C4B and CYP21A1P to  CYP21A2 probe
r a t i o s  i n  M L P A  w e r e  o b s e r v e d  ( F i g u r e  3 c - g ) .  T h e s e
patients were divided in two major groups according to
the status of exon 6 in the CYP21A1P/A2 chimeric genes:
patients 5-8 with mutant exon 6 are shown in Figure 3c,
and patients 9-20 with normal exon 6 in Figure 3d-g.
Chimeric CYP21A1P/A2 gene composition for alleles
in patients 5-7 seemed to be similar to that in patients 1
and 2 with mutant exon 6 and normal exon 8 (Figure 3a-c,
upper panels). However, C4A:C4B ratios were 2:3, sug-
gesting that both C4A copies may carry exon 19 corre-
sponding to C4B gene similar to that observed for patient
1. MLPA results for each family (data not shown) indi-
cated the segregation of both C4 and CYP21 chimeric
genes in the same allele (Figure 3c, left lower panel).
Patient 8 presented 2:1 MLPA ratio for C4A:C4B
sequences in agreement with Southern blotting. MLPA
showed that 21-hydroxylase gene copy in this case corre-
sponded to a complete pseudogene as the ratio for probes
CYP21A1P  3'-end and CYP21A2-exon 8 was 2:1 as
described above for patients 3 and 4 (Figure 3c, right
lower panel). SNPs in chimeric genes classified the mono-
modular alleles in patients 5-7 within haplotype II (table
3). Besides deletion, duplication and chimeric gene com-
position, MLPA analyzes could identify compound
heterozygosis for p.I172N in patient 7 (table 2; Figure 3c),
because the probe used for CYP21A2 exon 4 anneals to
the normal sequence at codon 172. Patient 8 showed hap-
lotype IV, which can be differentiated from III at the
SNPs g.1645G > C (SNP-rs6472; p.S268T) and at the
g.2110C>T (p.R356W) mutation (table 3).
MLPA results for patients 9-20 were shown in Figure
3d-g. Additionally, the probable localization of recombi-
nation breakpoint within CYP21A1P/A2 chimeric genes
divided them in two groups: patients 9-17 with break-
point between exon 3 and 4 (Figure 3d-f) and patients 18-
20 between exon 1 and intron 2 (Figure 3g). A combina-
tion of mono- and a probable tetramodular allele was
considered for patient 9 after analysis of allelic segrega-
tion in the family (Figure 2e). This was the most probable
combination to explain the relative intensity for
C4A[7.0]:C4B[6.0] (2:3) and for CYP21A2[3.7]:CYP21A1P[3.2]
(1:4) fragments in the patient. The mother presented
ratios of 2:1 for C4A[7.0]:C4B[5.4]  and 1:3 for
CYP21A2[3.7]:CYP21A1P[3.2] and was positive for p.P30L,
IVS2-13A/C > G and Δ8 mutations in ASO-PCR experi-
ments indicating a deleted allele with CL6N sequence.
The daughter inherited the 30-kb deleted allele from the
mother, therefore she should carry an allele with three
copies of each C4B and CYP21A1P to produce the rela-
tive intensities observed in the Southern blot (Figure 2e,
lanes 2 and 3). Patients 10 and 11 were compound
heterozygotes for tri- and monomodular alleles. These
genotypes may explain the 2:2 ratio for C4A  and  C4B
genes observed in Southern blot (Figure 2d). However, a
2:2 ratio for C4A:C4B in MLPA experiments has been
observed only for patient 11. Patient 10 showed a 2:3 gene
ratio, which is probably due to a positive hybridizationCoeli et al. BMC Medical Genetics 2010, 11:104
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signal for exon 19 C4B probe within the C4A gene copy in
the paternal trimodular allele, deduced from the family
analysis, therefore his most probable genotype is shown
in Figure 3d (middle panel). An additional difficulty in
interpreting MLPA results for patient 10 was that he also
carried p.Q318X in CYP21A2 gene copy of the paternal
inherited trimodular allele indicated in ASO-PCR experi-
ments (table 2). As CYP21A2 exon 8 MLPA probe anneals
to the normal sequence at codon 318, the result expected
in this case was a ratio of 2:1 for probes CYP21A1P
3'UTR to CYP21A2 exon 8, if both pseudogenes in the
trimodular allele were mutant in codon 318. However a
ratio 2:3 was obtained. Analysis of his parents (data not
shown) indicated that the two pseudogenes in the pater-
nal trimodular allele might carry the normal sequence in
codon 318 (Figure 3d, middle panel). The monomodular
alleles carried by patients 10 and 11 were classified,
respectively, within haplotype V and VI (table 3).
Patients 12-14 presented 2:2 MLPA ratios for C4A:C4B
contrasting with the 2:1 obtained on Southern blot (Fig-
ure 2c). In these cases, familial analysis demonstrated
that the bimodular alleles they carry in compound
heterozygosis with monomodular alleles, probably, con-
tain C4A genes formed by 5'-end C4A[7.0], C4A exon 17,
but exon 19 corresponds to C4B specific sequences (Fig-
ure 3e). The monomodular allele in patient 12 corre-
sponds to haplotype VI, whereas patients 13 and 14 carry
haplotype VII (table 3). Haplotype VI differs from VII by
the -449A>G (SNP-rs28361032) and g.395T > C (SNP-
rs6462).
Patients 15-19 demonstrated C4A:C4B ratios of 2:1 in
both Southern blotting and MLPA (Figure 3f-g). A 3:0
ratio in MLPA for C4A:C4B was observed for patient 20,
whereas Southern blotting showed a ratio of 2:1. This
result might indicate a C4A gene copy with a 6.0-kb Taq I
fragment in which exon 17 sequences correspond to C4A
and C4B specific sequences at exon 19 are absent, there-
fore the most probable genotype in this case is shown in
Figure 3g (right lower panel). MLPA indicated compound
heterozygosis for p.I172N in patients 17 and 19 (table 2;
Figure 3f,g). Likewise, it also detected compound
heterozygosis with p.Q318X mutation in patient 18 (table
2; Figure 3g). The recombination breakpoint indicated in
MLPA for patients 15-17 was between exon 3 - 4 (Figure
3f). Sequencing data indicated haplotype V for alleles in
patients 15 and 16 and haplotype VII for patient 17 (table
3). The recombination breakpoint indicated in MLPA for
patients 18-20 was between exon 1 and intron 2 (Figure
3f-g). However, sequencing results suggested distinct
alleles within this group. In haplotype VIII, which is
shared by patients 18 and 19, the recombination break-
point was probably located between the SNP
560_566insG and 602A > C (SNP-rs6451) as shown in
table 3. Whereas, the recombination breakpoint for the
allele carried by patient 20 (table 3, haplotype IX) was
probably located at the beginning of intron 2 since it car-
ried the variant A at the g.419 position (SNP - rs6448),
which is more frequent in CYP21A2 gene and the nucle-
otide C at 547 position that is characteristic of the
CYP21A2 gene.
Sequencing 170 CYP21A2  genes from obligate
heterozygote individuals and CYP21A1P sequences from
59 control individuals indicated that p.P34L was not pres-
ent in any gene or pseudogene sequences, whereas
heterozygosis for p.H62L was observed in the pseudo-
gene of four individuals (data not shown). Therefore,
p.P34L seems to be a novel mutation not derived from
pseudogene, whereas p.H62L showed a frequency of 3.4%
in pseudogenes.
Discussion
This study reports two novel deletion alleles in Brazilian
patients with 21-hydroxylase deficiency and describes the
variability of C4/CYP21 monomodular alleles evaluated
by combining Southern blot, ASO-PCR, MLPA and
sequencing techniques. The occurrence of different chi-
meric genes in Brazilian patients had not been reported
before. Although Real-Time PCR and HLA-haplotypes
would be alternative techniques to estimate, respectively,
C4  and  CYP21A2  copy number [35-37] and founder
effect they were not available for this work.
By combining different techniques we characterized
monomodular alleles carrying CYP21A1P/A2 chimeric
genes in genotypes that were compound heterozygous
w i t h  b i  -  o r  t r i m o d u l a r  a l l e l e s  b e a r i n g  p s e u d o g e n e -
derived mutations, including a bimodular allele carrying
p.R356W mutation associated to the rare 3.9-kb C4B
fragment (table 2, patient 16; Figure 2c), described before
in a non-disease causing allele [38]. Patient 9 who inher-
ited from the mother the monomodular allele might also
carry a tetramodular allele inherited from the father,
however a more detailed study is required to confirm the
tetramodular configuration for this allele that also carry a
novel g.60G > A (TGG > TGA) nucleotide change causing
the p.W19X mutation. The same mutation had been
described before as a result of the TGG > TAG nucleotide
change [39].
In general, data were convergent independently on the
technique used. However, patients with alleles carrying a
C4B/A or C4A/B gene and those in compound heterozy-
gosis with trimodular alleles could be misinterpreted as
carrying large gene conversions if only MLPA had been
used, because C4 probes resulted in signals indicative of
alleles without C4B deletion. Patients 1 and 2, are typical
examples. The 6.4-kb Taq I fragment identified in patient
2 is generally a marker for a deletion that results from
unequal crossover between a C4A[7.0] and a short C4B[5.4]
gene [26,40]. Such fragment is indicative of CYP21A1PCoeli et al. BMC Medical Genetics 2010, 11:104
http://www.biomedcentral.com/1471-2350/11/104
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deletion in monomodular alleles. It is found with a fre-
quency of 11% in the general population and do not cause
21-hydroxylase deficiency [12] and would not be recog-
nized in MLPA assay. The 6.4-kb gene variant is here
described for the first time in association with a
CYP21A1P/A2  gene in a case of 21-hydroxylase defi-
ciency. Alleles bearing CYP21A1P  deletions have been
proposed as premutation for generating CYP21A2
deleted alleles [41]. It can be speculated that an allele
bearing  C4B/A[6.4] and  CYP21A1P  deletion might have
influenced the formation of the monomodular allele in
which the deleted allele seems to have been generated in
at least two steps of unequal crossovers. However, those
events must have happened several generations ago
because the mutated allele had been segregating in this
family for three generations. Additionally, those recombi-
nation events might have introduced novel nucleotide
variants such as the -289T > C SNP in the 5'-promoter
region of CYP21A1P/A2. The T variant at nucleotide 395,
which is most frequent in CYP21A2  gene and a rare
1253G > A SNP within intron 5, which is described only
in the CYP21A1P as a rare polymorphic nucleotide posi-
tion, were also identified in this CYP21A1P/A2 chimeric
gene. Therefore haplotype I was uniquely found in patient
2. In a paper published before [42], data obtained with
ELISA assays also showed differences in C4 protein levels
between patients 1 and 2. Low level of C4A protein was
observed for patient 1 whereas patient 2 showed low level
of C4B protein. Although C4A and C4B genes share 99%
sequence identities, the proteins they encode have differ-
ent hemolytic activities, covalent affinities to antigens
and immune complexes, and serological reactivities
[12,43]. C4A gene copies producing proteins with electro-
phoretical characteristics of C4A but acting antigenically
as C4B have been described in association to 30-kb dele-
tion haplotypes [20,44]. Differences conferring specific
binding affinities are located within exon 26 [45], there-
fore monomodular allele in patient 1 may have 5'-end of
C4A as indicated by 7.0-kb fragment and C4B sequences
from exon 19 to 3'-end as indicated by MLPA and ELISA
assays. Similarly, patients 5, 6 and 7 also carried a C4A[7.0]
fragment with 3'-end C4B  sequences as denoted by
Southern blot and MLPA results. These patients together
with patient 1 grouped within haplotype II, which is simi-
lar to those described in several populations
[15,20,46,47]. In addition, patient 20 showed positive sig-
nal for C4A gene but no signal for C4B probe (3:0) in
MLP A. This result indicate that exon 17 in the C4B[6.0]
gene probably corresponded to C4A sequences and the
patient had been described as having very low immune
response toward C4B antiserum [42]. Although this allele
was not associated to 30-kb deletion, it illustrates C4 gene
variability that influences MLPA results.
Both haplotypes III and IV carry a complete CYP21A1P
pseudogene copy indicating that the recombination
breakpoint should map within the 5 kb that separate 3'-
end CYP21A2 and the exon 32 of TNXB gene. They dif-
fered because haplotype III showed the C allelic variants
in both g.1645 and g.2110 (p.R356W) nucleotides
whereas G and T, respectively, were observed in haplo-
type IV (table 3). Polymorphisms in CYP21A1P pseudo-
gene are known to be common [40], therefore those
haplotypes could be originated from unequal crossovers
involving bimodular alleles carrying different pseudogene
variants. Recombination within 3'-end CYP21A2 seems
t o  b e  f r e q u e n t  s i n c e  i t  h a s  b e e n  r e p o r t e d  b y  d i f f e r e n t
research groups [15,41] including as a de novo event in
which deleted alleles were generated [48,49].
A group of ten genes had recombination breakpoints
identified between exon 3 and 4. Haplotype V diverged
from the VI and VII because the alleles did not carry the
pseudogene-derived p.P30L, but showed p.P34L and
p.H62L mutations in exon 1. p.H62L has been recently
described in association with p.P453S in patients with the
NC form of 21-hydroxylase deficiency [50,51]. In order to
investigate whether p.P34L and p.H62L were rare
pseudogene-derived mutations that have arisen in this
chimeric gene through unequal crossover between gene
and pseudogene, since they are flanked by CYP21A1P-
like sequences, we tested 170 CYP21A2 genes from obli-
gate heterozygous individuals and CYP21A1P sequences
from 59 control individuals. Here we demonstrated that
p.H62L might be originated in CYP21A1P since it was
found in 3.4% pseudogene sequences. However, p.P34L
was not found in any pseudogene sequences, therefore its
origin remains unclear. Also, this haplotype showed the G
variant at nucleotide -308 in the CYP21A1P/A2 5'-pro-
moter region. Interestingly, this position is considered
polymorphic only in CYP21A1P with frequencies varying
from 0.1% to 0.3% in Chineses and Africans from Nigeria
(NCBI-SNP database). Different mutations in exon 1
together with rare 5'-end SNP characterize a novel haplo-
type that seems to be frequent in Brazilian patients carry-
ing monomodular alleles since it corresponded to 20% (4/
20) of total 30-kb deleted alleles reported here as causing
21-hydroxylase deficiency. Probably, haplotype V have
arisen in Brazil from an African ancestral since Brazilian
population is highly miscigenated with populations from
different origins including Africans of Benin Gulf region
[52]. This haplotype might have segregated with 21-
hydroxylase deficiency through an isolated founder effect
for 30-kb deletion alleles. Main differences between hap-
lotype VI and VII was found in -449 and g.395 nucle-
otides (table 3). The -449 position is considered to be
ambiguous only in the pseudogene (SNP # rs28361032)
whereas 395 is polymorphic in both gene and pseudogeneCoeli et al. BMC Medical Genetics 2010, 11:104
http://www.biomedcentral.com/1471-2350/11/104
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sequences (SNP # rs6462) but there are no frequency data
for the any of their allelic variants.
Haplotypes VIII and IX were separated because they
showed different recombination breakpoints within
intron 2. Those two haplotypes presented the CYP21A1P
promoter region and p.P30L mutation as pseudogene-
derived sequences and they are not very frequent in other
populations [15,53].
CYP21A1P/A2 chimeric genes can be correlated with
SW or SV forms of 21-hydroxylase deficiency depending
on the mutations they carry [15,20,46,47]. The variability
verified among 30-kb alleles with CYP21A1P/A2 chime-
ric genes present in different genotypes did not influence
the phenotypes observed (tables 1, 2). Therefore, patients
1-6, 9-10 and 12-16 presented SW form of 21-hydroxy-
lase deficiency as expected for homozygosis or com-
pound heterozygosis for haplotypes I-VII and mutations
that severely affect the enzyme activity (tables 1, 2). Simi-
larly, compound heterozygote patients for haplotypes I-
VII and p.I172N or p.V281L mutations presented, respec-
tively, SV or NC forms of the disease (tables 1, 2, patients
7, 11, 17). Patients carrying haplotypes VIII and IX pre-
sented SV phenotype independently if they were com-
pound heterozygous with a SV (tables 1, 2; p.I172N,
patient 19) or SW mutations (tables 1, 2; p.Q318X and
IVS2-13A/C > G, patients 18 and 20, respectively) indi-
cating a synergistic effect of CYP21A1P promoter region
and p.P30L upon the enzyme activity as proposed before
[54].
Our study showed that the combination of Southern
blot and ASO-PCR/direct sequencing with MLP A tests
may constitute an option for mapping and better charac-
terize chimeric genes on RCCX monomodular alleles,
especially in populations with high allelic diversity such
as that in Brazil. MLPA has been proposed as a candidate
with good potential to be used in neo-natal screening and
in pre-natal diagnosis because it can be performed with
very low amount of DNA [55]. Eventually, MLPA may
substitute time-consuming Southern blot in cases were
HCA diagnosis is urgent as it managed to estimate the
CYP21A1P/A2 borders in almost all cases. However, to
distinguish between deletions and large gene conversions
in genetic studies searching for detailed allelic informa-
tion, it would be more informative if more C4 and CYP21
probes were included in the analysis.
Conclusions
Our study showed that the combination of Southern blot
and ASO-PCR/direct sequencing with MLPA tests may
constitute an option for mapping and better characterize
chimeric genes on RCCX monomodular alleles, espe-
cially in populations with high allelic diversity such as
that in Brazil. MLPA has been proposed as a candidate
with good potential to be used in neo-natal screening and
in pre-natal diagnosis because it can be performed with
very low amount of DNA [55]. Eventually, MLPA may
substitute time-consuming Southern blot in cases were
HCA diagnosis is urgent as it managed to estimate the
CYP21A1P/A2 borders in almost all cases. However, to
distinguish between deletions and large gene conversions
in genetic studies searching for detailed allelic informa-
tion, it would be more informative if more C4 and CYP21
probes were included in the analysis.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
FBC carried out part of Southern blot, the MLPA and sequencing experiments
and sequence alignment; FCS, RDB and RJP participated in ASO-PCR experi-
ments for pseudogene-derived mutations and SNPs; MA, LCP and IFL partici-
pated in Southern blot and AS0-PCR studies of seven families; SHVLM, MTMB
and GGJ were responsible for diagnosis and management of patients and par-
ticipated in the design of the study; MPM conceived the study, and partici-
pated in its design and coordination and also drafted the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
Authors would like to thank Maria Madalena Vasconcelos Rosa for technical 
support and Dr. Márcio José da Silva from sequencing facility. This work was 
supported by Fundação de Amparo à Pesquisa do Estado de São Paulo 
(FAPESP - grants # 92/03332-6, 97/07622-2, 01/08150-4, 05/00981-5 and FCS 
received scholarship # 03/01785-0), Coordenação de Aperfeiçoamento de Pes-
soal de Nível Superior (FBC, MA, IFL), Conselho Nacional de Desenvolvimento 
Científico e Tecnológico (CNPq - Brasil).
Author Details
1Laboratório de Genética Molecular Humana, Centro de Biologia Molecular e 
Engenharia Genética, Universidade Estadual de Campinas, Campinas, SP, Brasil, 
2Departamento de Pediatria/Centro de Investigação em Pediatria, Faculdade 
de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brasil 
and 3Departamento de Clínica Médica, Disciplina de Endocrinologia, 
Faculdade de Ciências Médicas, Universidade Estadual de Campinas, 
Campinas, SP, Brasil
References
1. New MI: Inborn errors of adrenal steroidogenesis.  Mol Cel Endocrinol 
2003, 211:75-83.
2. White PC, Speiser PW: Congenital adrenal hyperplasia due to 21-
hydroxylase deficiency.  Endocrine Reviews 2000, 21:245-291.
3. Keegan CE, Killeen AA: An overview of molecular diagnostic of steroid 
21-hydroxylase deficiency.  J Mol Diagnostic 2001, 3:49-54.
4. Carroll MC, Campbell RD, Bentley DR, Porter RR: A molecular map of the 
human major histocompatibility complex class III region linking 
complement genes C4, C2 and factor B.  Nature 1984, 307:237-241.
5. White PC, Grossberger D, Onufer BJ, Chaplin DD, New MI, Dupont B, 
Strominger JL: Two genes encoding steroid 21-hydroxylase are located 
near the genes encoding the fourth complement in man.  Proc Natl 
Acad Sci USA 1985, 82:1089-1093.
6. Higashi Y, Yoshioka H, Yamane M, Gotoh O, Fujii-Kuriyama Y: Complete 
nucleotide sequence of two steroid 21-hydroxylase genes tandemly 
arranged in human chromosome: a pseudogene and a genuine gene.  
Proc Natl Acad Sci USA 1986, 83:2841-2845.
7. White PC, New MI, Dupont B: Structure of human steroid 21-
hydroxylase genes.  Proc Natl Acad Sci USA 1986, 83:5111-5115.
8. Yang Z, Mendoza AR, Welch TR, Zipf WB, Yu CY: Modular variations of the 
human major histocompatibility complex class III genes for serine/
threonine kinase RP, complement component C4, steroid 21-
hydroxylase CYP21, and tenascin TNX (the RCCX module). A 
Received: 31 October 2009 Accepted: 29 June 2010 
Published: 29 June 2010
This article is available from: http://www.biomedcentral.com/1471-2350/11/104 © 2010 Coeli et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Medical Genetics 2010, 11:104Coeli et al. BMC Medical Genetics 2010, 11:104
http://www.biomedcentral.com/1471-2350/11/104
Page 12 of 13
mechanism for gene deletions and disease associations.  J Biol Chem 
1999, 274:12147-12156.
9. Dangel AW, Mendoza AR, Baker BJ, Daniel CM, Carroll MC, Wu LC, Yu CY: 
The dichotomous size variation of human complement C4 genes is 
mediated by a novel family of endogenous retroviruses, which also 
establishes species-specific genomic patterns among Old World 
primates.  Immunogenetics 1994, 40:425-436.
10. Tassabehji M, Strachan T, Anderson M, Campbell RD, Collier S, Lako M: 
Identification of a novel family of human endogenous retroviruses and 
characterization of one family member, HERV-K(C4), located in the 
complement C4 gene cluster.  Nucleic Acids Res 1994, 22:5211-5217.
11. Chu X, Rittner C, Schneider PM: Length polymorphism of the human 
complement component C4 gene is due to an ancient retroviral 
integration.  Exp Clin Immunogenet 1995, 12:74-81.
12. Blanchong CA, Zhou B, Rupert KL, Chung EK, Jones KN, Sotos JF, Zipf WB, 
Rennebohm RM, Yu Yung C: Deficiencies of human complement 
component C4A and C4B and heterozygosity in length variants of RP-
C4-CYP21-TNX (RCCX) modules in caucasians. The load of RCCX 
genetic diversity on major histocompatibility complex-associated 
disease.  J Exp Med 2000, 191:2183-2196.
13. Schneider PM, Carroll MC, Alper CA, Rittner C, Whitehead AS, Yunis EJ, 
Colten HR: Polymorphism of the human complement C4 and steroid 
21-hydroxylase genes. Restriction fragment length polymorphisms 
revealing structural deletions, homoduplications, and size variants.  J 
Clin Invest 1986, 78:650-657.
14. Koppens PF, Hoogenboezem T, Degenhart HJ: Duplication of the 
CYP21A2 gene complicates mutation analysis of steroid 21-
hydroxylase deficiency: characteristics of three unusual haplotypes.  
Hum Genet 2002, 111:405-10.
15. Lee HH: Chimeric CYP21P/CYP21 and TNXA/TNXB genes in the RCCX 
module.  Mol Gen Met 2005, 84:4-8.
16. Carroll MC, Palsdottir A, Belt KT, Porter RR: Deletion of complement C4 
and steroid 21-hydroxylase genes in the HLA class III region.  EMBO J 
1985, 4:2547-2552.
17. Werkmeister JW, New MI, Dupont B, White PC: Frequent deletion and 
duplication of the steroid 21-hydroxylase genes.  Am J Hum Genet 1986, 
39:461-469.
18. White PC, Vilek A, Dupont B, New MI: Characterization of frequent 
deletions causing steroid 21-hydroxylase deficiency.  Proc Natl Acad Sci 
USA 1988, 85:4436-4440.
19. Morel Y, David M, Forest MG, Betuel H, Hauptman G, Andre J, Bertrand J, 
Miller WL: Gene conversions and rearrangements cause discordance 
between inheritance of forms of 21-hydroxylase deficiency and HLA 
types.  J Clin Endocrinol Metab 1989, 68:592-599.
20. Donohoue PA, Jospe N, Migeon CJ, Van Dop C: Two distinct areas of 
unequal crossingover within the steroid 21-hydroxylase genes 
produce absence of CYP21B.  Genomics 1989, 5:397-406.
21. Lee HH: Diversity of the CYP21P-like gene in CYP21 deficiency.  DNA Cell 
Biol 2005, 24:1-9.
22. Paldosttir A, Fossdal R, Arnason A, Edwards JH, Jennson O: Heterogeneity 
of human C4 gene size, a large intron (6.6 kb) is present in all C4A 
genes and some C4B genes.  Immunogenetics 1987, 25:299-304.
23. Haglund-Stengler B, Martin Ritzén E, Gustafsson J, Luthman H: 
Haplotypes of the steroid 21-hydroxylase gene region encoding mild 
steroid 21-hydroxylase deficiency.  Proc Natl Acad Sci USA 1991, 
88:8352-8356.
24. Torresani T, Biason-Lauber A: Congenital adrenal hyperplasia: diagnostic 
advances.  J Inherit Metab Dis 2007, 30:563-575.
25. Lee HH, Chang JG, Tsai CH, Tsai FJ, Chao HT, Chung B: Analysis of the 
chimeric CYP21P/CYP21 gene in steroid 21-hydroxylase deficiency.  
Clin Chem 2000, 46:606-611.
26. Lee HH, Niu DM, Lin RW, Chan P, Lin CY: Structural analysis of the 
chimeric CYP21P/CYP21 gene in steroid 21-hydroxylase deficiency.  J 
Hum Genet 2002, 47:517-522.
27. Friães A, Rêgo AT, Aragüés JM, Moura LF, Mirante A, Mascarenhas MR, Kay 
TT, Lopes LA, Rodrigues JC, Guerra S, Dias T, Teles AG, Gonçalves J: 
CYP21A2 mutations in Portuguese patients with congenital adrenal 
hyperplasia: identification of two novel mutations and 
characterization of four different partial gene conversions.  Mol Genet 
Metab 2006, 88:58-65.
28. Concolino P, Mello E, Minucci A, Giardina E, Zuppi C, Toscano V, 
Capoluongo E: A new CYP21A1P/CYP21A2 chimeric gene identified in 
an Italian woman suffering from classical congenital adrenal 
hyperplasia form.  BMC Med Genet 2009, 22:10-72.
29. De Araujo M, Sanches MR, Suzuki LA, Guerra G Jr, Farah SB, De Mello MP: 
Molecular Analysis of CYP21 and C4 Genes in Brazilian Families the 
Classical Congenital Adrenal Hyperplasia.  Brazilian J Med Biol Res 1996, 
29:1-13.
30. Bachega TA, Billerbeck AE, Madureira G, Arnhold IJ, Medeiros MA, 
Marcondes JA, Longui CA, Nicolau W, Bloise W, Mendonca BB: Low 
frequency of CYP2B deletions in Brazilian patients with congenital 
adrenal hyperplasia due to 21-hydroxylas deficiency.  Hum Hered 1999, 
49:9-14.
31. Sambrook J, Fritsch EF, Maniatis TE: Molecular cloning, a laboratory 
manual.  New York: Cold Spring Harbor; 1989. 
32. Wilson RC, Wei JQ, Cheng KC, Mercado AB, New MI: Rapid 
deoxyribonucleic acid analysis by allele-specific polymerase chain 
raction for detection of mutations in the 21-hydroxylase gene.  J Clin 
Endocrinol Metab 1995, 80:1635-1640.
33. MRC-Holland - SALSA MLPA kit P050 CAH   [http://www.mrc-
holland.com/WebForms/
WebFormProductDetails.aspx?Tag=tz2fAPIAupLo0TRBqtiGHA||&ProductO
ID=dVNA4DAAaOA|]
34. Taylor CF, Charlton RS, Burn J, Sheridan E, Taylor GR: Genomic deletions in 
MSH2 or MLH1 are a frequent cause of hereditary non-polyposis 
colorectal cancer: identification of novel and recurrent deletions by 
MLPA.  Hum Mutat 2003, 22:428-433.
35. Parajes S, Quinterio C, Domínguez F, Loidi L: A simple and robust 
quantitative PCR assay to determine CYP21A2 gene dose in the 
diagnosis of 21-hydroxylase deficiency.  Clin Chem 2007, 53:1577-84.
36. Szilagyi A, Blasko B, Szilassy D, Fust G, Sasvari-Szekely M, Ronai Z: Real-
time PCR quantification of human complement C4A and C4B genes.  
BMC Genet 2006, 10:1.
37. Kleinle S, Lang R, Fischer GF, Vierhapper H, Waldhauser F, Födinger M, 
Baumgartner-Parzer SM: Duplications of the functional CYP21A2 gene 
are primarily restricted to Q318X alleles: evidence for a founder effect.  
J Clin Endocrinol Metab 2009, 94:3954-8.
38. Koppens PF, Hoogenboezem T, Degenhart HJ: A rare TaqI polymorphism 
in a human complement C4 gene is caused by an additional restriction 
site in the first intron.  Immunol Lett 1992, 34:93-97.
39. Kharrat M, Tardy V, M'Rad R, Maazoul F, Jemaa LB, Refaï M, Morel Y, 
Chaabouni H: Molecular genetic analysis of Tunisian patients with a 
classic form of 21-hydroxylase deficiency: identification of four novel 
mutations and high prevalence of Q318X mutation.  J Clin Endocrinol 
Metab 2004, 89:368-74.
40. Koppens PF, Hoogenboezem T, Degenhart HJ: CYP21 and CYP21P 
variability in steroid 21-hydroxylase deficiency patients and in the 
general population in the Netherlands.  Eur J Hum Genet 2000, 
8:827-836.
41. Sinnott P, Collier S, Costigan C, Dyer PA, Harris R, Strachan T: Genesis by 
meiotic unequal crossover of a de novo deletion that contributes to 
steroid 21-hydroxylase deficiency.  Proc Natl Acad Sci USA 1990, 
87:2107-2111.
42. Guerra-Junior G, Grumach AS, Lemos-Marini SH, Kirschfink M, Condino 
Neto A, de Araujo M, De Mello MP: Complement 4 phenotypes and 
genotypes in Brazilian patients with classical 21-hydroxylase 
deficiency.  Clin Exp Immunol 2009, 155:182-188.
43. Dodds AW, Ren XD, Willis AC, Law SK: The reaction mechanism of the 
internal thioester in the human complement component C4.  Nature 
1996, 379:177-179.
44. Donohoue PA, Guethlein L, Collins MM, Van Dop C, Migeon CJ, Bias WB, 
Schmeckpeper BJ: The HLA-A3, Cw6,B47,DR7 extended haplotypes in 
salt losing 21-hydroxylase deficiency and in the Old Order Amish: 
identical class I antigens and class II alleles with at least two crossover 
sites in the class III region.  Tissue Antigens 1995, 46:163-172.
45. Chung EK, Yang Y, Rennebohm RM, Lokki ML, Higgins GC, Jones KN, Zhou 
B, Blanchong CA, Yu CY: Genetic sophistication of human complement 
components C4A and C4B and RP-C4-CYP21-TNX (RCCX) modules in 
the major histocompatibility complex.  Am J Hum Genet 2002, 
71:823-837.
46. Chu X, Braun-Heimer L, Rittner C, Schneider PM: Identification of the 
recombination site within the steroid 21-hydroxylase gene (CYP21) of 
the HLA B47,DR7 haplotype.  Exp Clin Immunogenet 1992, 9:80-85.Coeli et al. BMC Medical Genetics 2010, 11:104
http://www.biomedcentral.com/1471-2350/11/104
Page 13 of 13
47. L'Allemand D, Tardy V, Grüters A, Schnabel D, Krude H, Morel Y: How a 
patient homozygous for a 30-kb deletion of the C4-CYP 21 genomic 
region can have a nonclassic form of 21-hydroxylase deficiency.  J Clin 
Endocrinol Metab 2000, 85:4562-4567.
48. Fasano MB, Winkelstein JA, LaRosa T, Bias WB, McLean RH: A unique 
recombination event resulting in a C4A*Q0,C4B*Q0 double null 
haplotype.  J Clin Invest 1992, 90:1180-1184.
49. Koppens P, Smeets H, de Wijs IJ, Degenhart H: Mapping of a de novo 
unequal crossover causing a deletion of the steroid 21-hydroxylase 
(CYP21A2) gene and a non-functional hybrid tenascin-X (TNXB) gene.  J 
Med Genet 2003, 40:e53.
50. Soardi FC, Barbaro M, Lau IF, Lemos-Marini SH, Baptista MT, Guerra-Junior 
G, Wedell A, Lajic S, de Mello MP: Inhibition of CYP21A2 enzyme activity 
caused by novel missense mutations identified in Brazilian and 
Scandinavian patients.  J Clin Endocrinol Metab 2008, 93:2416-2420.
51. Menassa R, Tardy V, Despert F, Bouvattier-Morel C, Brossier JP, Cartigny M, 
Morel Y: p.H62L, a rare mutation of the CYP21 gene identified in two 
forms of 21-hydroxylase deficiency.  J Clin Endocrinol Metab 2008, 
93:1901-1908.
52. Figueiredo MS, Kerbauy J, Goncalves MS, Arruda VR, Saad ST, Sonati MF, 
Stoming T, Costa FF: Effect of ?-Thalassemia and ?-Globin Gene Cluster 
Haplotypes on the Hematological and Clinical Features of Sickle 
Anemia in Brazil.  Am J Hematol 1996, 53:72-76.
53. Killeen AA, Sane KS, Orr HT: Molecular and endocrine characterization of 
a mutation involving a recombination between the steroid 21-
hydroxylase functional gene and pseudogene.  J Steroid Biochem Mol 
Biol 1991, 38:677-686.
54. Kyllo JH, Collins MM, Donohoue PA: Constitutive human steroid 21-
hydroxylase promoter gene and pseudogene activity in steroidogenic 
and nonsteroidogenic cells with the luciferase gene as a reporter.  
Endocr Res 1995, 21:777-91.
55. Sørensen KM, Andersen PS, Larsen LA, Schwartz M, Schouten JP, Nygren 
AO: Multiplex Ligation-Dependent Probe Amplification Technique for 
Copy Number Analysis on Small Amounts of DNA Material.  Anal Chem 
2008, 80:9363-9368.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/11/104/prepub
doi: 10.1186/1471-2350-11-104
Cite this article as: Coeli et al., Novel deletion alleles carrying CYP21A1P/A2 
chimeric genes in Brazilian patients with 21-hydroxylase deficiency BMC 
Medical Genetics 2010, 11:104